ATP2B1 gene Silencing Increases Insulin Sensitivity through Facilitating Akt Activation via the Ca\(^{2+}\)/calmodulin Signaling Pathway and Ca\(^{2+}\)-associated eNOS Activation in Endothelial Cells

Yang Long\(^1,2\), Ji-yi Xia\(^3\), Shao-wei Chen\(^4\), Chen-lin Gao\(^1\), Guan-nan Liang\(^2\), Xue-mei He\(^2\), Jian Wu\(^2\), Chun-xia Jiang\(^1\), Xin Liu\(^2\), Wei Huang\(^1\), Qin Wan\(^{1,2}\), Yong Xu\(^{1,3}\)

\(^{1}\) Department of Endocrinology, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, P R China;
\(^{2}\) Laboratory of Endocrinology, Experimental Medicine Center, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, P R China;
\(^{3}\) Key Laboratory of Medical Electrophysiology of Ministry of Education, Collaborative Innovation Center for Prevention and Treatment of Cardiovascular Disease, Institute of Cardiovascular Research, Southwest Medical University, Luzhou, 646000, Sichuan, P R China;
\(^{4}\) Medical Reproduction Center, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, P R China.

Corresponding authors: Qin Wan and Yong Xu are co-corresponding on this work, and reprint requests should be addressed to Yong Xu. Qin Wan MD., Department of Endocrinology, The Affiliated Hospital of Southwest Medical University, 25 TaiPing Street, LuZhou, 646000, Sichuan, China; Tel: 86-138827246971 E-mail: qinwan@163.com Yong Xu MD., Department of Endocrinology, The Affiliated Hospital of Southwest Medical University, 25 TaiPing Street, LuZhou, 646000, Sichuan, China; Key Laboratory of Medical Electrophysiology of Ministry of Education, Collaborative Innovation Center for Prevention and Treatment of Cardiovascular Disease, Institute of Cardiovascular Research, Southwest Medical University, Luzhou, 646000, Sichuan, P R China; Tel: 86-13980255895 E-mail: xywyll@aliyun.com

© Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Received: 2017.02.14; Accepted: 2017.06.28; Published: 2017.09.05

Abstract

Endothelial cell insulin resistance may be partially responsible for the higher risk of atherosclerosis and cardiovascular disease in populations with insulin resistance and type 2 diabetes mellitus (T2DM). A genome-wide association study revealed a significant association between the ATPase plasma membrane Ca\(^{2+}\) transporting 1 (ATP2B1) gene and T2DM in two community-based cohorts from the Korea Association Resource Project. However, little is known about the implication of the ATP2B1 gene on T2DM. In the present study, we investigated the role of the ATP2B1 gene in endothelial cell insulin sensitivity. ATP2B1 gene silencing resulted in enhanced intracellular calcium concentrations and increased insulin-induced Akt activation compared to that in the negative siRNA-transfected HUVECs (Human Umbilical Vein Endothelial Cells). The elevated insulin sensitivity mediated by ATP2B1 gene silencing was Ca\(^{2+}\)/calmodulin-dependent, as verified by administration of the calcium chelator BAPTA-AM or the calmodulin-specific antagonist W7. Moreover, higher levels of phosphorylation of eNOS (Ser1177) were observed in ATP2B1-silenced HUVECs. In addition to BAPTA-AM and W7, L-NAME, an eNOS antagonist, abolished insulin-induced Akt phosphorylation at Ser473 in both si-Neg and si-ATP2B1-transfected endothelial cells. These results indicate that the enhanced insulin sensitivity in ATP2B1-silenced endothelial cells is alternatively dependent on an increase in intracellular Ca\(^{2+}\) and the subsequent activation of the Ca\(^{2+}\)/calmodulin/eNOS/Akt signaling pathway. In summary, ATP2B1 gene silencing increased insulin sensitivity in endothelial cells by directly modulating the Ca\(^{2+}\)/calmodulin signaling pathway and via the Ca\(^{2+}\)/calmodulin/eNOS/Akt signaling pathway alternatively.

Key words: ATPase plasma membrane Ca\(^{2+}\) transporting 1; Plasma Membrane Calcium ATPase 1; Endothelial Insulin Resistance; Calcium; Calmodulin.

Introduction

Insulin, a peptide hormone secreted by islet β cells, plays a well-defined role in regulating endothelial cell function. There are at least two major pathways to mediate the signaling of insulin in endothelial cells. The activation of the IR/IRS/PI3K/Akt (Insulin Receptor/Insulin Receptor Substrate/Phosphatidylinositol 3-Kinase/Protein kinase B) signaling pathway leads to the phosphorylation of endothelial nitric oxide synthase (eNOS) at Ser1177 and subsequent nitric oxide (NO)
PMCA1 protein plays a crucial role in the regulation of intracellular Ca²⁺ concentration and the Ca²⁺-associated signaling pathway.

Thus, the current study was designed to examine the effects of silencing ATP2B1 gene expression on intracellular Ca²⁺ concentration in endothelial cells and to explore how silencing of the ATP2B1 gene modifies insulin sensitivity through the Ca²⁺-associated signaling pathway. Furthermore, we investigated whether the Ca²⁺-associated signaling pathway in endothelial cells, characterized by selective inhibition of the IR/IRS/PI3K/Akt signaling pathway, has been reported to be associated with the conditions of insulin resistance and type 2 diabetes mellitus (T2DM) [2, 6]. In addition, it may partially be responsible for the higher risk of atherosclerosis and cardiovascular disease in populations with insulin resistance and T2DM [2, 7]. Moreover, supporting evidence from rodent experiments shows that selective insulin resistance plays an important role in the development of atherosclerosis [8-10].

Accumulating evidence shows that there is strong association between SNPs related to ATPase plasma membrane Ca²⁺ transporting 1 (ATP2B1) gene and hypertension in different ethnic groups, such as European [11], Korean [12], Japanese [13], and Chinese [14]. In experimental studies, higher blood pressure was observed in ATP2B1 siRNA-treated mice [15], systemic heterozygous ATP2B1-null mice [16], and vascular smooth muscle cell-targeted ATP2B1 gene KO mice [17]. Additionally, impaired NO production may be one of the mechanisms involved in ATP2B1 gene knockdown-induced hypertension [16]. Moreover, a genome-wide association study revealed that rs17249754, a SNP located in the intron region of the ATP2B1 gene, was significantly associated with T2DM in two community-based cohorts from the Korea Association Resource Project [18]. However, we know little about the implication of the ATP2B1 gene on T2DM.

The ATP2B1 gene, located on chromosome 12q21.33, encodes Plasma Membrane Calcium ATPase 1 (PMCA1)[19]. In addition, it is well known that PMCA1 protein plays a crucial role in the maintenance of intracellular Ca²⁺ homeostasis by ejecting Ca²⁺ ions from the cytosol [20]. Knockdown of the ATP2B1 gene results in higher intracellular Ca²⁺ concentration [16]. Furthermore, previous studies have shown that increased intracellular Ca²⁺ concentrations are responsible for insulin-induced Akt activation [21]. Therefore, we hypothesized that the dysregulation of the ATP2B1 gene expression could regulate endothelial cell insulin sensitivity through modifying intracellular Ca²⁺ concentration and the Ca²⁺-associated signaling pathway.

Materials and Methods

Cell culture

HUVECs (ScienCell Research Laboratories, CA, USA) were cultured in Endothelial cell medium (ECM) (ScienCell Research Laboratories, CA, USA) supplemented with 1× endothelial cell growth supplement (ScienCell Research Laboratories, CA, USA), 100 U of penicillin/ml, 100 μg of streptomycin/ml, and 5% FBS (ScienCell Research Laboratories, CA, USA) in a 37°C, 5% CO₂ incubator. HUVECs were transfected with 100 nM negative-siRNA (Si-Neg) or ATP2B1-siRNA (Si-ATP2B1). The ATP2B1 siRNA for homo sapiens, consisting of 3 target-specific 19-25 nt siRNAs designed to knock down ATP2B1 gene expression, was purchased from Santa Cruz Biotechnology (Santa Cruz Biotechnology, CA, USA. Catalog Number: sc-42596).

Measurement of the intracellular Ca²⁺ concentration

The concentration of Ca²⁺ was measured using Fluo-3-acetoxymethyl ester (fluo-3/AM) according to the protocol described by Mima S et al. with slight modifications [22]. Briefly, 48 h after transfection HUVECs were harvested and washed with HANKS buffer with calcium, and then suspended in serum-free low-glucose DMEM with 5 μmol/L fluo-3/AM, 0.1% BSA, 0.04% Pluronic F127, and 2 mmol/L probenecid for 30 min at 37°C. After washing twice with HANKS buffer with calcium, the cells were suspended in assay buffer containing 2 mmol/L probenecid and transferred to a 96-well black plate. The fluorescence signals from cells were measured with a spectrofluorophotometer by recording the excitation signals at 490 nm and the emission signal at 530 nm. Maximum and minimum fluorescence values (Fmax and Fmin) were detected by adding the calcium inopore A23187 or A23187 plus 5 mmol/L EGTA (in Ca²⁺-free medium, respectively). [Ca²⁺]i was calculated according to the following equation: [Ca²⁺]i =Kd (F-Fmin) / (Fmax-F), where Kd is the apparent
dissociation constant (400 nmol/L) of the fluorescence dye-Ca²⁺ complex.

**Western blotting**

To analyze the levels of phosphor-Akt (Ser 473) and phosphor-eNOS (Ser 1177), the siRNA-transfected HUVECs were starved of serum overnight followed by pretreatment with or without 30 μM W7 for 30 min, 10 μM BAPTA-AM for 90 min or 50 μM L-NAME for 2 hours respectively. Then, the HUVECs were stimulated with 100 nM insulin for 30 minutes. HUVECs lysates were prepared in 150 μl of lysis buffer (Beyotime Institute of Biotechnology, Shanghai, China) on ice in 1.5 ml microtubes for 15 min and centrifuged for 5 min at 12,000 g at 4°C. The supernatant was collected and protein concentrations were measured using the Thermo Scientific Pierce BCA Protein Assay Kit (Pierce Biotechnology, Rockford, USA), and then the protein samples were stored at -80°C until further examination.

For the Western blotting, cell lysates were subjected to SDS-PAGE and immunoblotting was performed using specific antibodies against eNOS (1:800) (Santa Cruz Biotechnology, Inc, Taxes, USA), phosphor-eNOS (Ser 1177) (1:800) (Cell Signaling Technology, Inc, Boston, USA), PMCA1 (1:600) (Santa Cruz Biotechnology, Inc, Taxes, USA), Akt (1:1000) (Cell Signaling Technology, Inc, Boston, USA), phosphor-Akt (Ser 473) (1:2000) (Cell Signaling Technology, Inc, Boston, USA) and GAPDH (1:5000) (ZSGB-Bio, Inc., Beijing, China).

**Co-immunoprecipitation**

For the co-immunoprecipitation experiment, the siRNA-transfected HUVECs were stimulated with 100 nM insulin after overnight serum starvation. HUVECs were lysed in RIPA buffer for IP (Beyotime Institute of Biotechnology, Shanghai, China). After the lysates were precleared with protein A/G agarose beads (Beyotime Institute of Biotechnology, Shanghai, China), they were incubated with specific antibodies against calmodulin (1:50) (Bioworld Technology, Minneapolis, Minnesota, USA) overnight at 4°C. Then, the protein A/G agarose beads were added and incubated for 2 h. The supernatants were discarded. After washing with RIPA for IP 3 times, 2× SDS loading buffer were added to the protein A/G agarose beads. The levels of Akt, that co-immunoprecipitated with the antibody against calmodulin, were analyzed by Western blotting.

**Statistics**

Data are expressed as the mean ± SD from 3-6 separate experiments. Data were analyzed by one-way ANOVA. P-values of less than 0.05 were considered statistically significant.

**Results**

**Silencing of the ATP2B1 gene in HUVECs results in increased levels of insulin-induced phosphorylation of Akt at serine 473**

As determined by Western blotting, the PMCA1 protein levels were significantly decreased by about 70% in the si-ATP2B1-transfected HUVECs compared to that in the negative control siRNA-transfected cells (Figure 1A). Then, we detected the levels of phosphor-Akt (Ser473) in HUVECs by Western blotting to explore whether silencing of the ATP2B1 gene influenced insulin sensitivity. As shown in Figure 1B and 1C, higher levels of insulin-induced phosphorylation of Akt at serine 473 were found in the ATP2B1-silenced HUVECs cells, which were increased to almost 1.8 times as much as that in the control cells. These data indicate that ATP2B1 gene silencing could modify insulin sensitivity in endothelial cells.

**Increased insulin sensitivity in the ATP2B1-silenced HUVECs cells may be due to a calcium-dependent signaling pathway**

Then, we hypothesized that increased insulin-induced phosphor-Akt (Ser473) levels in the ATP2B1-silenced HUVECs cells would be calcium-dependent. Consistent with the effects of insulin, the calcium ionopore A23187 (calcimycin) induced 70% higher phosphor-Akt (Ser473) levels in the ATP2B1-silenced HUVECs compared to that in the control cells (Figure 2A, 2B). These data implicate that the effect of ATP2B1 gene silencing is mediated by an increase in the intracellular Ca²⁺ concentration. To confirm whether intracellular calcium concentrations in HUVECs are altered following ATP2B1 gene silencing, we used the Fluo-3/AM fluorescence assay. As shown in Figure 2C, the intracellular calcium concentration was approximately 450 nM in the ATP2B1-silenced HUVECs and was 1.7 times as much as that in the control cells. Furthermore, insulin could not increase Akt phosphorylation at Ser 473 both in the control cells and the ATP2B1-silenced HUVECs that were co-cultured with BAPTA-AM, an intracellular Ca²⁺ chelator (Figure 2D, 2E). These results indicate that, similar to the insulin-mediated Akt activation in normal endothelial cells, the increased insulin sensitivity in ATP2B1-silenced HUVECs is calcium-dependent.
Increased insulin sensitivity in ATP2B1-silenced HUVECs is dependent on the calcium-calmodulin-eNOS signaling pathway

It has been reported that eNOS, a Ca²⁺/calmodulin-dependent enzyme, plays an important role in regulating the activation of Akt[23]. Therefore, we focused on the potential contribution of eNOS. In our current article, we observed that the insulin-stimulated phosphorylation levels of eNOS at site ser1177 in the ATP2B1-silenced HUVECs were 1.3 times as compared with that in the control cells (Figure 4A, 4B). To confirm whether eNOS mediates the activation of Akt, we inhibited the eNOS activity by pretreatment with an eNOS inhibitor, L-NAME. As shown in Figure 4C, 4D and 4E, the activation of Akt was abolished by the inhibition of eNOS activity with L-NAME, indicating that Akt can be activated by an eNOS-dependent pathway. Next, we explored whether higher eNOS activity in the ATP2B1 gene siRNA treated-endothelial cells was induced by a calcium-calmodulin dependent manner. Similar to insulin-induced phosphor-Akt (Ser473) (Figure 2 and 3), the intracellular Ca²⁺ chelator BAPTA-AM and the calmodulin antagonist W7 abolished the levels of insulin-induced phosphor-eNOS (Ser1177) in both the ATP2B1-silenced HUVECs and the control cells (Figure 4F, 4G, 4H and 4I). The above results suggest that increased insulin sensitivity in the ATP2B1-silenced HUVECs may be mediated via a higher level of intracellular calcium concentration and that the effect is dependent on the calcium-calmodulin-eNOS signaling pathway.

Discussion

rs17249754, a SNP located in the intron region of the ATP2B1 gene, was found to be associated with a higher risk of T2DM [18]. However, we know little about the implications of the ATP2B1 gene on T2DM.
In the present study, our data demonstrated that ATP2B1 gene silencing increased insulin sensitivity in endothelial cells by enhancing intracellular Ca\(^{2+}\) concentrations and the Ca\(^{2+}/\)calmodulin signaling pathway directly. Moreover, ATP2B1 gene silencing also resulted in greater insulin-induced eNOS activity via the Ca\(^{2+}/\)calmodulin signaling pathway. Additionally, the Ca\(^{2+}\)-associated activation of eNOS was involved in modifying insulin sensitivity in the ATP2B1-silenced HUVECs.

![Figure 2](http://www.ijbs.com)

**Figure 2.** The increased insulin sensitivity in ATP2B1-silenced HUVECs cells may be due to calcium-dependent signaling pathway. HUVECs were starved of serum overnight before stimulation with 500 nM A23187 for 30 min. A. Representative Western blotting results of p-Akt, Akt and GAPDH (n=4). B. Fold changes of phosphor-Akt vs. total Akt relative to its basal levels in the control cells without A23187 stimulation were quantified by densitometry. *P<0.05, vs. negative siRNA-transfected cells without A23187 stimulation. #P<0.05, vs. negative siRNA-transfected cells stimulated with A23187. C. The intracellular concentrations of Ca\(^{2+}\) were measured using fluo-3/AM in HUVECs 48 h after transfection (n=6). *P<0.05, vs. cells transfected with negative siRNA. Following 2 hours of BAPTA administration HUVECs were stimulated with 100 nM insulin for 30 min. D. Representative Western blotting results of phosphor-Akt (Ser473) (n=4). E. Fold changes of phosphor-Akt vs. total Akt relative to its basal levels in control cells were quantified by densitometry. *P<0.05, vs. cells transfected with negative siRNA; #P<0.05, vs. ATP2B1-silenced cells without BAPTA-AM pretreatment.
Almost eight years ago, the ATP2B1 gene was identified to be associated genome-wide significantly with systolic and diastolic blood pressure and/or with hypertension [11, 12, 24]. Since then, strong associations between the ATP2B1 gene loci and blood pressure or hypertension have also been reported in different ethnic groups [13, 14, 18]. Additionally, SNPs related to ATP2B1 gene have been found to be genetically associated with pulse pressure, coronary artery disease and coronary artery calcification and myocardial infarction in chronic kidney disease [19]. These genetic studies in large populations indicate that the ATP2B1 gene has pleiotropic effects on the cardiovascular system. However, little is known about how the ATP2B1 gene effects on cardiovascular function. Because of the association of the ATP2B1 gene with hyperlipidemia and diabetes, it is hypothesized that indirect effects of the ATP2B1 gene on metabolism may play a potential role in regulating cardiovascular function [18]. Evidence from experimental studies shows that increase in blood pressure induced by ATP2B1 gene knockdown may be due to impaired endothelium-dependent relaxation, increased contractility of mesenteric arteries, or elevated phenylephrine-induced vasoconstriction [19]. In our current study, ATP2B1 gene silencing led to increased insulin-induced Akt activation in endothelial cells that were cultured in vitro. The potential role of the ATP2B1 gene in endothelial cell insulin sensitivity could also be an underlying mechanism involved in its effect on the cardiovascular system.

In the current study, we hypothesized that increased insulin-induced phosphor-Akt (Ser473) levels in the ATP2B1-silenced HUVECs cells would be calcium-dependent. Intracellular Ca\(^{2+}\), which exists ubiquitously in mammalian cells, is a well-known secondary messenger and is critical in controlling a variety of cellular processes [25]. It has been reported that the changes in intracellular Ca\(^{2+}\) concentration are involved in regulating Akt activity. SKF-96365, a calcium antagonist, has been reported to decrease intracellular Ca\(^{2+}\) concentrations through inhibiting the store-operated Ca\(^{2+}\) entry-mediated Ca\(^{2+}\) influx which consequently attenuates Akt activity in colon cancer cell lines [26]. Furthermore, increased intracellular Ca\(^{2+}\) is responsible for insulin-induced Akt activation, which results in leptin secretion in adipocytes [21]. These results indicate that Ca\(^{2+}\) is required for insulin-induced Akt phosphorylation at Ser473 in endothelial cells. In the present study, we observed that ATP2B1 gene silencing resulted in higher intracellular Ca\(^{2+}\) and simultaneously led to enhanced insulin-induced AKT activity. Furthermore, administration of a calcium chelator BAPTA-AM prior to insulin treatment blocked insulin-induced Akt phosphorylation at Ser473. Therefore, the enhanced insulin sensitivity observed in the ATP2B1-silenced endothelial cells may be due to higher levels of intracellular Ca\(^{2+}\).
Figure 4. Increased insulin sensitivity in ATP2B1-silenced HUVECs is dependent on the calcium-calmodulin-eNOS signaling pathway. HUVECs were stimulated with 100 nM insulin after overnight serum starvation. A. Representative Western blotting results of p-eNOS, eNOS and GAPDH \((n=4)\). B. Fold changes of phosphor-eNOS vs. total eNOS relative to its basal levels in control cells were quantified by densitometry. HUVECs were treated with L-NAME for 2 hours before they were stimulated with insulin. \(* 0.05<P<0.001\), vs. negative siRNA-transfected cells without insulin stimulation. \#P<0.05, vs. cells transfected with negative siRNA. C. Representative Western blotting results of p-Akt, Akt, p-eNOS, eNOS and GAPDH \((n=3)\). Fold changes of phosphor-eNOS vs. total eNOS (D) and phosphor-Akt vs. total Akt (E) relative to the basal levels in control cells were quantified by densitometry. \(* P<0.05\), vs. negative siRNA-transfected cells. \#P<0.05, vs. si-Neg cells precultured without L-NAME. HUVECs were stimulated with 100 nM insulin after being treated with BAPTA or W7 for 2 hours. Representative Western blotting of p-eNOS, eNOS and GAPDH in cells pretreated with BAPTA (F) or W7 (H) \((n=3)\). Fold changes of phosphor-eNOS vs. total eNOS in cells cultured with BAPTA (G) or W7 (I) were quantified by densitometry. \(* P<0.05\), vs. negative siRNA-transfected cells. \#P<0.05, vs. si-Neg cells without BAPTA-AM or W7 pretreatment.
Calmodulin, one of the most important intracellular Ca²⁺ sensors, interacts with many different proteins and is involved in regulating a wide variety of cellular physiological functions [27]. Recent evidence suggests that calmodulin plays a critical role in regulating the activity of Akt. Research data collected by nuclear magnetic resonance confirms that the Pleckstrin homology domain (PHD), a conserved domain that is found in the N-terminus of Akt, is a critical domain that binds with calmodulin [28-30]. These results indicate that the direct binding between calmodulin and Akt may be involved in regulating Akt activity. However, the previous studies have drawn different conclusions about whether the binding of calmodulin with Akt results in the decrease or increase in Akt activity. One of the previous studies declared that calmodulin competed with PI(3,4,5)₃ for the PH domain of Akt, thereby decreasing the affinity of PI(3,4,5)₃ and attenuating Akt activity[30]. Others have reported that calmodulin could mediate EGF-induced Akt activation by binding and targeting Akt to the plasma membrane to be activated by PI-3 kinase in c-Myc-overexpressing mouse mammary carcinoma cells [28, 31]. In addition, the results obtained in PC12 cells and chicken spinal cord motor neurons showed that Ca²⁺ and calmodulin play a central role in the activation of Akt [32]. Furthermore, a novel calmodulin-binding motif was found in the Akt PHD, which was mapped to two loops that are adjacent to the PI(3,4,5)₃ binding site and these results suggest a synergetic relationship between calmodulin and PI(3,4,5)₃ in the activation of Akt [28]. In line with these previous studies, we observed that the specific antagonist of calmodulin W7 almost completely abolished the insulin-induced Akt phosphorylation at serine 473 in the control cells and the ATP2B1-silenced endothelial cells. Additionally, the effect was mediated by the binding of Akt to calmodulin as shown in the co-immunoprecipitation experiment. These results indicate that calmodulin is necessary for insulin-induced Akt activation in endothelial cell. In addition, the interaction between calmodulin and Akt may be an important mechanism that explains why knockdown of ATP2B1 gene increases insulin sensitivity. Difference in experimental design maybe a possible reason for the contradictory conclusion in the research conducted by Rihe Liu [30]. These studies were performed using the pulldown assay, phosphoinositide membrane strip and GST-tagged Akt(PHD) protein [30], whereas others were conducted with native and untagged Akt(PHD) protein and physiologically relevant membrane mimetic containing PS [28]. Furthermore, our research was performed in primary endothelial cells cultured in vitro, and others in mammary carcinoma cell lines [31, 33], PC12, and chicken spinal cord motoneurons [32]. To clarify how calmodulin interacts with Akt and how the interplay between calmodulin and Akt regulates Akt activation, further investigations are required.

eNOS, also known as endothelial nitric oxide synthase, is specifically expressed in endothelial cells and is responsible for NO generation [34]. The enzymatic activity of eNOS has been reported to be dependent on Ca²⁺/calmodulin binding [35, 36]. PMCsAs (a group of proteins encoded by ATP2B1-4 gene), with its emerging role in regulating Ca²⁺/calmodulin-dependent enzymes, removes calcium from the cell to the extracellular environment and inhibits the activity of eNOS by directing it to low-calcium cellular microenvironments [37]. Additionally, PMCsAs proteins reduce NO production by binding with eNOS and inhibiting its activity [37]. Consistently, in the present research higher levels of intracellular Ca²⁺ concentration and phosphor-eNOS (Ser1177) were observed in the ATP2B1-silenced HUVECs. However, impaired NO production and lower levels of phosphor-eNOS (Ser1177) were reported in systemic heterozygous ATP2B1 null mice [16]. The differences in experimental design may account for the adverse results in these studies. First, the research conducted by Akira Fujiwara and his colleagues was performed in systemic heterozygous ATP2B1-null mice in vivo [16], while we and Angel L. Armesilla [37] conducted studies in endothelial cells cultured in vitro. Alternatively, ATP2B1 gene was knockdown systemically but not specifically in endothelial cells in mice [16]. Therefore, the possibility of other mechanisms cannot be ruled out. Furthermore, ATP2B1 gene silencing-mediated increases in eNOS activity in endothelial cells were observed at 48-72 hours after the transient transfection of siRNA in the present study. However, the decrease in eNOS activity mediated by systemic heterozygous ATP2B1 gene knockdown was examined in mice at 3 months of age [16]. To clarifying the influence of the ATP2B1 gene on the activity of eNOS, further investigations are warranted in endothelial cell-specific ATP2B1 gene knockout mice.

In addition to eNOS, Akt is also known as a Ca²⁺/calmodulin-dependent enzyme [29]. Additionally, an abundance of evidence has shown that Akt can activate eNOS by directly phosphorylating eNOS at serine 1177[38]. However, eNOS is also involved in regulating the activation of Akt through its catalyzed product NO [23]. In this study, in line with the activity of Akt higher levels of phosphor-eNOS (Ser1177) were observed in the ATP2B1-silenced HUVECs. Moreover, the eNOS
inhibitor L-NAME blocked the activation of both eNOS and Akt by insulin. Additionally, phosphor-eNOS (Ser1177) levels were also abolished by the calcium chelator BAPTA-AM and the calmodulin antagonist W7. These results suggest that in addition to the Ca\textsuperscript{2+}/calmodulin/Akt signaling pathway, enhanced insulin sensitivity in the ATP2B1-silenced endothelial cells are dependent on an increase in intracellular Ca\textsuperscript{2+} and the subsequent activation of the Ca\textsuperscript{2+}/calmodulin/eNOS/Akt signaling pathway.

In summary, we reported that ATP2B1 gene silencing increased insulin sensitivity in endothelial cells in the present study. Enhancing intracellular Ca\textsuperscript{2+} concentration by ATP2B1 gene silencing, may be one of the central mechanisms involved in the increased insulin sensitivity observed in the ATP2B1-silenced endothelial cells. Additionally, facilitated Akt Activation via the Ca\textsuperscript{2+}/calmodulin signaling pathway and Ca\textsuperscript{2+}-associated eNOS activation was involved in modifying insulin sensitivity in the ATP2B1-silenced HUVECs. Furthermore, in attempt to showing how the PMCA1 protein regulates insulin-induced Akt phosphorylation, a figure of proposed model is provided (Figure 5). However, there are some limitations in the present study. First, this research was conducted on HUVECs cultured in vitro, and in vivo animal experiments were not performed. Therefore, we do not know whether the silencing of the ATP2B1 gene increases insulin sensitivity in endothelial cells in vivo. Second, our results suggest that facilitated Akt activation via the Ca\textsuperscript{2+}/calmodulin signaling pathway and Ca\textsuperscript{2+}-associated eNOS activation is involved in modifying insulin sensitivity in the ATP2B1-silenced HUVECs, but the relationship between Akt and eNOS is not clearly established and the mechanism that is involved in how the regulation of Akt activity by activated eNOS is still unclear. Third, calmodulin, as mentioned above, is a versatile intracellular Ca\textsuperscript{2+} sensors that interacts with many different proteins, including Akt [27], eNOS [27], and, most importantly, PMCA1 protein [19, 39] etc. Use of the calmodulin inhibitor W7 may mask the effects of other Ca\textsuperscript{2+}/calmodulin-dependent proteins, such as PMCA1 protein, on Akt activation. Therefore, it is not clear whether the interaction between calmodulin and PMCA1 protein is also involved in the increased insulin sensitivity induced by ATP2B1 gene silencing. Last, as shown in Figure 1A, siRNA treatment of the ATP2B1 gene decreased but not totally knockout the expression of the PMCA1 protein. Therefore, we cannot draw the conclusion that the interaction between calmodulin and the Akt PH domain is crucial for Akt activation.

Figure 5. Proposed model of the role of the PMCA1 protein in regulating insulin-induced Akt phosphorylation. ATP2B1 gene silencing, which results in decreased expression of the PMCA1 protein, leads to enhanced intracellular Ca\textsuperscript{2+} concentrations in endothelial cells. Enhanced Ca\textsuperscript{2+} concentrations by ATP2B1 gene silencing facilitate insulin-induced Akt activation through Ca\textsuperscript{2+}/calmodulin signaling pathway. Moreover, ATP2B1 gene silencing results in greater insulin-induced eNOS activity via the Ca\textsuperscript{2+}/calmodulin signaling pathway. Additionally, the Ca\textsuperscript{2+}-associated activation of eNOS was involved in modifying insulin sensitivity in ATP2B1-silenced HUVECs. ATP2B1: ATPase plasma membrane Ca\textsuperscript{2+} transporting 1; PMCA1: Plasma Membrane Calcium ATPase 1; IR: insulin receptor; IRS1: insulin receptor substrate 1; CaM: calmodulin; Akt: protein kinase B; eNOS: endothelial nitric oxide synthase; NO: nitric oxide; PM: plasma membrane; PIP2: Phosphatidylinositol-4,5-biphosphate; PIP3: Phosphatidylinositol-3,4,5-triphosphate; PI3K: Phosphatidylinositol 3-Kinase.
Acknowledgement

This work was supported by the Joint Project of the People's Government of Luzhou and Sichuan Medical University under Grant no 2015SX-0032 and by the Affiliated Hospital of Southwest Medical University under Grant no 15046.

Disclaimers

The views expressed in the submitted article are our own and not an official position of the institution or funder.

Competing Interests

The authors have declared that no competing interest exists.

References

1. Kuboki K, Jiang ZY, Takahara N, et al. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific role of vascular activation of insulin. Circulation. 2001;104:676-81.
2. King GL, Park K, Li Q. Selective Insulin Resistance and the Development of Cardiovascular Diseases in Diabetes: The 2015 Edwin Bierman Award Lecture. Diabetes. 2016; 65: 1462-71.
3. Oliver FJ, de la Rubia G, Feener EP, et al. Stimulation of endothelin-1 gene expression by insulin in endothelial cells. J Biol Chem. 1991; 266: 23252-6.
4. Schneider DJ, Absher PM, Ricci MA. Dependence of augmentation of arterial endothelial cell expression of plasminogen activator inhibitor type 1 by insulin on soluble factors released from vascular smooth muscle cells. Circulation. 1997; 96: 2686-76.
5. Muniyappa R, Montagnani M, Koh KK, et al. Cardiovascular actions of insulin. Endocr Rev. 2007; 28: 463-91.
6. Khamaisi M, Katagiri S, Keenan H, et al. PKCdelta inhibition normalizes the endothelial cell expression of plasminogen activator inhibitor type 1 by insulin in soluble factors released from vascular smooth muscle cells. Circulation. 1997; 96: 2686-76.
7. Laakso M, Sarlund H, Salonen R, et al. Asymptomatic atherosclerosis and insulin resistance. Arterioscler Thromb. 1991; 11: 1068-76.
8. Jiang ZY, Lin YW, Clement A, et al. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest. 1999; 104: 447-57.
9. Tsujiya K, Tanaka J, Shiuqiang Y, et al. FoxOs integrate pleiotropic actions of insulin in vascular endothelium to protect mice from atherosclerosis. Cell Metab. 2012; 15: 372-81.
10. Li Q, Park K, Li C, et al. Induction of vascular insulin resistance and endothelin-1 expression and acceleration of atherosclerosis by the overexpression of protein kinase C-beta isoform in the endothelium. Circ Res. 2013; 113: 418-27.
11. Levy D, Ehret GB, Rice K, et al. Genome-wide association study of blood pressure and hypertension. Nat Genet. 2009; 41: 677-87.
12. Cho YS, Go MJ, Kim YJ, et al. A large-scale genome-wide association study of Asian populations uncovers genetic factors influencing eight quantitative traits. Nat Genet. 2009; 41: 527-34.
13. Tsuchiya K, Tanaka J, Shuiqing Y, et al. FoxOs integrate pleiotropic actions of insulin in vascular endothelium to protect mice from atherosclerosis. Cell Metab. 2012; 15: 372-81.
14. Li Q, Park K, Li C, et al. Induction of vascular insulin resistance and endothelin-1 expression and acceleration of atherosclerosis by the overexpression of protein kinase C-beta isoform in the endothelium. Circ Res. 2013; 113: 418-27.
15. Kobayashi Y, Hirawa N, Tabara Y, et al. Mice lacking hypertension candidate gene ATP2B1 in vascular smooth muscle cells show significant blood pressure elevation. Hypertension. 2012; 59: 854-60.
16. Heo SG, Hwang JY, Uhm S, et al. Male-specific genetic effect on hypertension and metabolic disorders. Hum Genet. 2014; 133: 311-9.
17. Little R, Cartwright EJ, Neyses L, et al. Plasma membrane calcium ATPases (PMCA s) as potential targets for the treatment of essential hypertension. Pharmacol Ther. 2016; 159: 23-34.
18. Di Leva F, Domi T, Fedrizzi L, et al. The plasma membrane Ca2+ ATPase of animal cells: structure, function and regulation. Arch Biochem Biophys. 2008; 476: 65-74.